![\"\"](\"http:\/\/stateofthenation.info\/wp-content\/uploads\/2026\/11\/Screenshot-2026-11-11-at-7.21.49-AM.png\")
<\/p>\n<\/p>\n
A biotechnology startup backed by billionaire Peter Thiel has unveiled a disturbing new artificial intelligence (AI) system that it says can help parents create \u201cdesigner babies\u201d with significantly higher intelligence than naturally born children.<\/p>\n
Nucleus Genomics claims its new AI-powered model can rank IVF embryos by predicted intelligence, with an astonishing 14-point IQ gap between the highest- and lowest-scoring embryos in a batch of ten.<\/p>\n
While announcing Vitruvian, the company\u2019s latest set of \u201cgenetic optimization models,\u201d Nucleus Genomics founder Kian Sadeghi wrote<\/a>:<\/p>\n \u201cAI is rapidly getting smarter.<\/p>\n \u201cNow, humanity can too.<\/p>\n \u201cVitruvian\u2019s intelligence model can optimize embryo DNA for 14 IQ points \u2013 nearly a standard deviation,\u201d Sadeghi said.<\/p>\n He added that the models were trained using data from more than one million people and validated using more than 40,000 siblings.<\/p>\n AI Ranks Embryos by Predicted Intelligence<\/strong><\/p>\n Vitruvian does not genetically edit embryos.<\/p>\n Instead, the system analyzes embryos already created during an IVF cycle and scores them so parents can decide which one they want implanted.<\/p>\n Nucleus has also promoted embryo comparisons based on predicted height, eye color, hair color, and risks for conditions including breast cancer, type 2 diabetes, and autism.<\/p>\n According to the company\u2019s whitepaper<\/a>, the expected difference between the highest- and lowest-scoring embryo in a group of ten is 14.3 IQ points.<\/p>\n With five embryos, Nucleus puts the predicted spread at 10.8 points.<\/p>\n The company says selecting the highest-scoring embryo rather than an average embryo could produce an expected intelligence advantage of roughly half that spread.<\/p>\n That would mean an estimated gain of around seven IQ points from a batch of ten embryos and around five points from five embryos.<\/p>\n The five-embryo estimate is roughly double what researchers predicted only several years ago.<\/p>\n A 2019 study published<\/a> in Cell estimated an average gain of approximately 2.5 IQ points when screening a typical IVF cycle containing about five viable embryos, increasing to around three points with ten embryos.<\/p>\n Nucleus now says its system captures approximately 62% of the common genetic variation associated with cognitive ability.<\/p>\n Model Trained on Hundreds of Thousands of People<\/strong><\/p>\n According to the whitepaper, the intelligence model was trained using genetic association data from approximately 500,000 people.<\/p>\n It was then tested using roughly 40,000 siblings of European ancestry contained within the UK Biobank.<\/p>\n The \u201cIQ\u201d predicted by the model is based on the Biobank\u2019s verbal-numerical reasoning test.<\/p>\n Among siblings, Nucleus says the score accounts for around 19% of the variation in latent cognitive ability after adjusting for the reliability of the test.<\/p>\n Nucleus was founded by Sadeghi after he dropped out of college.<\/p>\n The company raised<\/a> a $14 million Series A round in January 2025, bringing its total funding to approximately $32 million.<\/p>\n Its investors include Thiel\u2019s Founders Fund, Alexis Ohanian\u2019s Seven Seven Six, and Balaji Srinivasan.<\/p>\n Nucleus initially offered adult genetic testing, including testing related to IQ, before expanding into IVF embryo scoring.<\/p>\n Watchdog Challenges \u2018Smartest Embryo\u2019 Claims<\/strong><\/p>\n The company\u2019s explosive claims have already drawn scrutiny.<\/p>\n Just one week before Vitruvian was unveiled, the National Advertising Division of BBB National Programs recommended<\/a> that Nucleus stop suggesting its IVF+ service can accurately determine which embryo will be the smartest.<\/p>\n The watchdog said the company\u2019s evidence \u201cfailed to establish the accuracy of identifying the highest-IQ embryo within a multi-embryo group.\u201d<\/p>\n Nucleus said it would appeal the decision, arguing that NAD\u2019s \u201cconclusions cannot be reconciled.\u201d<\/p>\n No ruling on that appeal could be located.<\/p>\n The American Society for Reproductive Medicine has also warned against<\/a> using this type of embryo screening in clinical practice.<\/p>\n In December, the organization\u2019s ethics and practice committees concluded that polygenic embryo screening \u201cis a nascent and unproven technology that should not be used clinically at this time.\u201d<\/p>\n